EDINBURGH, Scotland, Jan. 13, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that CEO Bryan Kobel will be presenting a corporate overview at the upcoming Sequire Investor Summit 2025. The conference is scheduled for January 21-23, 2025, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico. For more informati ...

EDINBURGH, Scotland, Jan. 6, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that its American Depository Shares (ADSs) has continued trading on the Nasdaq Global Select Market (Nasdaq) under the ticker symbol 'TCBP'. There has been no halt in trading and shares are expected to continue trading unabated. This pres ...

EDINBURGH, Scotland, Dec. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that shareholders have formally approved the recently announced 25% stock dividend. Today, TC BioPharm declared that last week's proposed special stock dividend was formally approved at today's General Meeting of the Company. The special ...

Clinical Trial Progress - The ACHIEVE UK clinical trial is a phase II study evaluating the efficacy of TCB008 in patients with AML or MDS/AML, focusing on refractory or relapsed disease [1] - Preliminary safety data shows the 5mL dose of TCB008 is well tolerated with no drug-related Adverse Events, aligning with the safety profile [2] - 3 patients have completed the full-dose regimen in the ACHIEVE Phase 2b trial with no drug-related Adverse Events observed [5] - 10 patients have received their first dose, 9 their second dose, 4 their third dose, and 3 their fourth and final dose [9] - 9 out of 10 recruited patients are in Cohort A (relapsed/refractory), while 1 patient is in Cohort B (remission with residual disease) [9] - Recruitment for the ACHIEVE trial has been successful, with over half of Cohort A patients recruited in less than 5 months [10] Company Overview - TC BioPharm is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for cancer treatment [3][11] - The company is the first to conduct phase II/pivotal clinical studies in oncology using gamma-delta T cell therapies [3] - TC BioPharm is conducting two investigator-initiated clinical trials, including a Phase 2b/3 pivotal trial for acute myeloid leukemia using its proprietary CryoTC technology [3] Future Plans and Expectations - The company plans to recruit 14 patients initially into Cohort A and B, with an additional 10 patients per cohort after confirming study endpoints, totaling 48 patients [9] - The immediate clinical focus is on high recruitment for Cohort B in 2025 and completing data review for Cohort A [6] - The CEO highlighted the potential for an expedited review due to the patients' stage and disease expression, with minimal residual disease representing a high opportunity for TCB008 [6]

EDINBURGH, Scotland, Dec. 18, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that its Board of Directors has approved a special dividend to its shareholders of 0.25 American Depositary Shares ("ADSs") for every 1 ADS held by shareholders, pending shareholder approval. The Company intends to hold a general meeting ...

On Wednesday, TC BioPharm (Holdings) PLC TCBP announced that its Board of Directors approved a special dividend of 0.25 American Depositary Shares for every 1 ADS held by shareholders, pending shareholder approval.The company intends to hold a general meeting of shareholders on Monday, December 30.The dividend is expected to be declared on December 30, 2024, and payable to shareholders who own the company's stock at the close of trading on January 02, 2025."We are extremely pleased to announce this special ...

Positive safety data, allowing for exploration of higher TCB008 doses 4 UK-based clinical sites recruiting patients, with a further 2 sites expected in H1 2025EDINBURGH, Scotland, Dec. 4, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced an update on the progression of the ACHIEVE UK Trial.As of this week, over hal ...

Financial Performance - Net loss for the six months ended June 30, 2024, was £5,308,407 compared to a net income of £357,976 for the same period in 2023, indicating a significant shift in financial performance [11]. - For the six months ended June 30, 2024, the net loss was £5.3 million compared to a net income of £0.4 million for the same period in 2023 [27]. - The company reported a basic net loss per share of £0.08 for the six months ended June 30, 2024, compared to a basic net income per share of £0.12 for the same period in 2023 [11]. - The accumulated deficit increased from £38,837,290 as of December 31, 2023, to £44,145,697 as of June 30, 2024, reflecting a worsening financial position [10]. - The total shareholders' equity decreased from £2,685,230 as of December 31, 2023, to £2,004,187 as of June 30, 2024, a decline of approximately 25.4% [10]. Assets and Liabilities - Total current assets decreased from £5,700,927 as of December 31, 2023, to £3,952,319 as of June 30, 2024, representing a decline of approximately 30.6% [8]. - Total liabilities decreased from £6,246,434 as of December 31, 2023, to £4,867,208 as of June 30, 2024, a reduction of about 22.1% [10]. - Cash and cash equivalents decreased from £2,462,609 as of December 31, 2023, to £1,004,329 as of June 30, 2024, a decline of approximately 59.3% [8]. - As of June 30, 2024, cash and cash equivalents amounted to approximately £1.0 million, with working capital of £393,857 [27]. - Prepaid expenses and other current assets decreased to £1,687,869 as of June 30, 2024, from £2,194,725 as of December 31, 2023 [61]. - Accounts payable and accrued liabilities decreased to £3,211,690 as of June 30, 2024, from £4,431,840 as of December 31, 2023 [62]. Operating Expenses - Total operating expenses decreased from £7,762,970 for the six months ended June 30, 2023, to £5,496,407 for the same period in 2024, reflecting a reduction of about 29.1% [11]. - Research and development expenses for the six months ended June 30, 2024, were £2,238,234, down from £4,037,332 in the same period of 2023, a decrease of approximately 44.5% [11]. - Cash used in operating activities for the six months ended June 30, 2024, was £5.1 million, a decrease from £6.8 million in the prior year [27]. - The Company recorded operating lease expenses of £177,674 for both the six months ended June 30, 2024, and 2023 [65]. Shareholder Information - The number of weighted-average common shares outstanding increased from 3,030,825 for the six months ended June 30, 2023, to 64,905,328 for the same period in 2024, indicating a substantial increase in share issuance [11]. - The weighted average number of shares outstanding increased to 64,905,328 for the six months ended June 30, 2024, compared to 3,030,825 for the same period in 2023 [49]. - The Company issued 24,692 ordinary shares prior to the IPO, with a fair value of £3.8 million [75]. - The Company issued 23,950 ADSs representing 4,790,000 ordinary shares in a public offering, resulting in gross proceeds of $2.0 million before expenses [113]. - The Company changed its ADS ratio from one ADS representing one ordinary share to one ADS representing twenty ordinary shares on December 15, 2023 [87]. Future Outlook - The company expects to continue incurring significant losses in the foreseeable future as it develops its clinical products [26]. - The company plans to raise additional capital to address future liquidity needs, which may include equity raises or other financing options [28]. - The company has substantial doubt about its ability to continue as a going concern without adequate liquidity [29]. Capital and Financing Activities - The company raised £6.2 million ($8.0 million) in August 2024 through the issuance of ordinary shares and pre-funded warrants [27]. - The Company entered into a Securities Purchase Agreement on August 28, 2024, resulting in gross proceeds of $6.0 million from the sale of 53,558 ADSs [115]. - The Company received approximately £3.1 million from the exercise of Existing Warrants by holders in May 2024 [85]. - The Company has received approximately $1.1 million in cash receipts from the exercise of warrants as of November 21, 2024 [27]. - The Company recognized an incremental fair value of £248,659 for modified share options granted to five grantees in March 2024 [98]. Compensation and Management - TC Biopharm (Holdings) PLC granted a one-time bonus of $125,000 to CEO Bryan Kobel and CFO Martin Thorp [117]. - Compensation for Chairwoman Arlene Morris increased to $75,000 per year, effective Q3 2024 [117]. - Compensation for Chairman of the Audit Committee James Culverwell increased to $65,000 per year, effective Q3 2024 [117].

EDINBURGH, Scotland, Oct. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today provides an update to its shareholders and highlighted the Company's operational achievements thus far in 2024. "The Company has made tremendous strides during the current year and bolstered its standing as a leading clinical-stage biopharmaceuti ...

Core Viewpoint - TC BioPharm confirms its compliance with all Nasdaq listing requirements and refutes rumors of potential delisting from the exchange [1][2] Company Compliance and Response - The company has stated that it is not in danger of being delisted from Nasdaq and remains compliant with all listing requirements [1][2] - TC BioPharm plans to take action against false claims that aim to create negative market dynamics [2] Company Overview - TC BioPharm is a clinical-stage biotechnology company focused on developing gamma-delta T cell therapies for cancer treatment, with human efficacy data in acute myeloid leukemia [4] - The company is a leader in this field and has conducted phase II/pivotal clinical studies in oncology [4] - TC BioPharm is currently conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line, including a Phase 2b/3 pivotal trial for acute myeloid leukemia using proprietary CryoTC technology [4]